3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
17
Carcinoma, Non-Small-Cell Lung
9
Squamous Cell Carcinoma of Head and Neck
7
Carcinoma, Hepatocellular
6
Triple Negative Breast Neoplasms
5
Small Cell Lung Carcinoma
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Colorectal Neoplasms
4
Stomach Neoplasms
3
Neoplasm Metastasis
3
Mesothelioma
2
Melanoma
2
Head and Neck Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Merkel Cell
2
Urinary Bladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Neuroendocrine
1
Anophthalmia with pulmonary hypoplasia
1
Interventions
pembrolizumab
51
Nivolumab
27
Gemcitabine
23
atezolizumab
19
Cisplatin
18
Carboplatin
18
enfortumab vedotin
15
avelumab
15
Mitomycin
14
Docetaxel
8
Ipilimumab
7
Paclitaxel
6
Injections
5
Cyclophosphamide
5
vinflunine
4
toripalimab
4
tislelizumab
4
lenvatinib
4
fludarabine
4
epacadostat
4
Pemetrexed
4
130-nm albumin-bound paclitaxel
4
sacituzumab govitecan
3
disitamab vedotin
3
Rogaratinib
3
Interleukin-2
3
ALT-803
3
vofatamab
2
valrubicin
2
rucaparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Transitional Cell
×
budigalimab
×
Clear all
NCT06632951
2025-08-11
LIVIGNO-3
AbbVie
Phase 2
Active not recruiting
150 enrolled